Tepmetko
What Tepmetko is used for
Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Tepmetko
- Active substance
- tepotinib
- Disease area
- Carcinoma, Non-Small-Cell Lung
- Medicine group
- Antineoplastic agents
- ATC code
- L01EX21
- Marketing authorisation holder
- Merck Europe B.V.
- Authorised in the EU since
- 2022
Official information
In the USA
Same active substance: Tepmetko
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Tepmetko used for?
Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
What is the active substance in Tepmetko?
Tepmetko contains tepotinib.
Who makes Tepmetko?
The EU marketing authorisation holder is Merck Europe B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU